Strict data privacy laws like the GDPR have significantly reduced biopharmaceutical R&D investment—especially among smaller firms—highlighting the need for U.S. policymakers to reform HIPAA, pass innovation-friendly federal privacy legislation, and invest in privacy-enhancing technologies to protect both privacy and progress in medical research.
